DIA EUROPE 2020

Back to Agenda

Navigating Multiple Stakeholder Perspectives on Clinical HTA Methodological Standards for EU Joint Assessments beyond 2020

Session Chair(s)

Manpreet Sidhu, PhD, MBA

Executive Principal, Head of Global HTA, Health Economics, Reimbursement and Out

ICON Clinical Research, United States

Navigating the most appropriate methods for EU JCAs will be a balancing act between regulatory, national HTA and EUnetHTA standards. This forum aims to explore requirement differences from the perspectives of three relevant stakeholders

Speaker(s)

Pragmatically addressing requirements from the submitted evidence packages, and challenges in mitigating uncertainty over long-term clinical benefits: The HTA Perspective

Niklas Hedberg, MPharm

Dental and Pharmaceutical Benefits Agency, TLV, Sweden

HTACG Co-Chair & Chief Pharmacist

Leveraging data with state-of-the-art assessment methods, and pragmatically addressing requirements across multiple countries: The Industry Perspective

Adam Parnaby

Bristol Myers Squibb, Belgium

Senior Director, Market Access Policy

EU cooperation on HTA post 2020: stronger synergies for stronger evidence

Flora Giorgio, MPharm

European Commission, Belgium

Deputy Head of Unit Medical Devices, DG SANTE – Medical Products and Innovation

Have an account?